Abstract
Systemic sclerosis (SSc) is a chronic connective tissue disease characterized by fibrosis and destruction of the microvasculature. Increased deposition of collagen and other extracellular matrix components affects not only the skin but most of the internal organs including lungs, heart, kidneys and the gastrointestinal (GI) tract. Within the GI tract, esophageal involvements are most frequently seen features. However, abnormalities in the small intestine, colon and anorectum may also occur. A retrospective study was performed to investigate the frequency and clinical relevances of GI involvement in patients with SSc. Charts of altogether 246 SSc patients were reviewed. This patient population included 40 males and 206 females, with a mean age of 54.2 years. In general, 176 of 246 patients (71.5%) had GI symptoms. Esophageal involvement including gastro-esophageal reflux disease (GERD), aperistalsis, pseudodiverticuli, etc. was the most common (62.6%). In addition, diseases of the stomach (31.7%), dysfunctions of the colon and anorectum (11.4%), as well as sclerosis of the biliary tract and other pancreato-biliary disorders (9.8%) also occurred. Diarrhea and malabsorption resulted in cachexia and other secondary complications leading to death in two cases. Our results support that GI manifestations are rather common in SSc. Apart from the esophagus, other GI complications in SSc are usually mild, however, early recognition is necessary to improve quality of life.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Seibold JR (2005) Scleroderma. In: Harris ED Jr, Budd RC, Firestein GS, Genovese MC, Sergent JS, Ruddy S, Sledge CB (eds) Kelley’s textbook of rheumatology, vol II, 7th edn. Elsevier Saunders, Philadelphia, pp 1279–1308
Marguerie C, Kaye S, Vyse T, Mackworth-Young C, Walport MJ, Black C (1995) Malabsorption caused by coeliac disease in patients who have scleroderma. Br J Rheumatol 34:858–861
Folwaczny C, Voderholzer W, Riepl RL, Schindlbeck N (1996) Clinical aspects, pathophysiology, diagnosis and therapy of gastrointestinal manifestations of progressive systemic scleroderma. Z Gastroenterol 34:497–508
Bernstein RM, Callender ME, Neuberger JM, Hughes GR, Williams R (1982) Anticentromere antibody in primary biliary cirrhosis. Ann Rheum Dis 41:612–614
Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581
Weston S, Thumshirn M, Wiste J, Camilleri M (1998) Clinical and upper gastrointestinal motility features in systemic sclerosis and related disorders. Am J Gastroenterol 93:1085–1089
Rose S, Young MA, Reynolds JC (1998) Gastrointestinal manifestations of scleroderma. Gastroenterol Clin North Am 27:563–594
Ponge T, Bruley des Varannes S (2002) Digestive involvement of scleroderma. Rev Prat 52:1896–1900
Poirier TJ, Rankin GB (1972) Gastrointestinal manifestations of progressive systemic scleroderma based on a review of 364 cases. Am J Gastroenterol 58:30–44
Cohen S, Fisher R, Lipshutz W, Turner R, Myers A, Schumacher R (1972) The pathogenesis of esophageal dysfunction in scleroderma and Raynaud’s disease. J Clin Invest 51:2663–2668
Sjögren RW (1994) Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 37:1265–1282
Sjögren RW (1996) Gastrointestinal features of scleroderma. Curr Opin Rheumatol 8:569–575
Marie I, Levesque H, Ducrotté P, Denis P, Hellot MF, Benichou J, Cailleux N, Courtois H (2001) Gastric involvement in systemic sclerosis: a prospective study. Am J Gastroenterol 96:77–83
Mittal BR, Wanchu A, Das BK, Ghosh PP, Sewatkar AB, Misra RN (1996) Pattern of gastric emptying in patients with systemic sclerosis. Clin Nucl Med 21:379–382
Franck-Larsson K, Hedenstrom H, Dahl R, Ronnblom A (2003) Delayed gastric emptying in patients with diffuse versus limited systemic sclerosis, unrelated to gastrointestinal symptoms and myoelectric gastric activity. Scand J Rheumatol 32:348–355
Marie I, Levesque H, Ducrotté P, Courtois H (1999) Involvement of the small intestine in systemic scleroderma. Rev Med Interne 20:504–513
Caserta L, de Magistris L, Secondulfo M (2003) Assessment of intestinal permeability and orocecal transit time in patients with systemic sclerosis: analysis of relationships with epidemiologic and clinical parameters. Rheumatol Int 23:226–230
Wang SJ, Lan JL, Chen DY, Chen YH, Hsieh TY, Lin WY (2001) Colonic transit disorders in systemic sclerosis. Clin Rheumatol 20:251–254
Heyt GJ, Oh MK, Alemzadeh N, Rivera S, Jimenez SA, Rattan S, Cohen S, Dimarino AJ Jr (2004) Impaired rectoanal inhibitory response in scleroderma (systemic sclerosis): an association with fecal incontinence. Dig Dis Sci 49:1040–1045
Wang SJ, Lan JL, Lan JL, Chen DY, Chen YH, Hsieh TY, Lin WY (2002a) Effects of cisapride on colonic transit in patients with progressive systemic sclerosis. Clin Rheumatol 21:271–274
Wang SJ, La JL, Chen DY, Chen YH, Hsieh TY, Lin WY (2002b) Effects of cisapride on oesophageal transit of solids in patients with progressive systemic sclerosis. Clin Rheumatol 21:43–45
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was supported by grant No 60/2001 from the Medical Research Council of Hungary (ETT) (Z.S.), and grant No T 048541 from the National Scientific Research Fund (OTKA) (Z.S.).
Rights and permissions
About this article
Cite this article
Szamosi, S., Szekanecz, Z. & Szűcs, G. Gastrointestinal manifestations in Hungarian scleroderma patients. Rheumatol Int 26, 1120–1124 (2006). https://doi.org/10.1007/s00296-006-0146-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-006-0146-z